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PredictabilityAbstract Drug release from various polymers is generally governed by type of polymer/s incorpo-
rated in formulation and mechanism of drug release from polymer/s. Single polymer may show one
or more mechanisms of drug release out of which one mechanism is majorly followed for drug
release. Some of the common mechanisms of drug release from polymers were, diffusion, swelling,
matrix release, leaching of drug, etc. Mechanism or rate of drug release from polymer or combina-
tion of polymers can be predicted by using different computational methods or models. These
models were capable of predicting drug release from its dosage form in advance without actual
formulating and testing of drug release from dosage form. Quantitative structure–property relation-
ship (QSPR) is an important tool used in prediction of various physicochemical properties of actives
as well as inactives. Since last several decades QSPR has been applied in new drug development for
reducing the total number of drugs to be synthesized, as it involves selection of the most desirable
compound of interest. This technique was also applied in predicting in vivo performance of drug/s
for various parameters. QSPR serves as a predictive tool to correlate structural descriptors of mol-
ecules with biological as well as physicochemical properties. Several researchers have contributed at
different extent in this area to modify various properties of pharmaceuticals. The present review is
focused on study of different polymers that inﬂuence the transportability proﬁles of drugs along
with application of QSPR either to study different properties of polymers that regulate drug release
or in predicting drug transportability from different polymer systems used in formulations.
ª 2012 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.
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speciﬁc time can be successfully achieved by the use of suitable
polymer/s. Therefore, selection of proper polymer system is a
critical step involved in formulation of drug into dosage form.
Type of polymer/s incorporated in formulation majorly deci-
des the mechanism and rate of drug release. Single polymer
may show one or more mechanisms of drug release, such as
diffusion, swelling, matrix release, leaching of drug, etc.; out
of which any one mechanism is majorly followed for drug re-
lease. Several computational methods or models are available
to predict the mechanism and/or rate of drug release from a
polymer or a combination of polymers. Such models will assist
in prediction of drug release in advance without actual
formulation of drug into suitable dosage form. QSPR is an
important tool used in the prediction of various physicochem-
ical properties of actives as well as inactives.
Commonly, physicochemical properties of polymers and re-
lease mechanism for polymer compositions were considered in
designing any formulation. However, several excipients espe-
cially polymers have shown pharmacological interaction with
physiological components such as membrane situated efﬂux
pumps. Such interactions could lead to altered drug bioavail-
ability. Membrane situated efﬂux pump inhibitors were gener-
ally preferred to increase the substrate drug concentration
inside the cell. These inhibitors are classiﬁed majorly into
two groups: polymeric inhibitors and small molecule inhibitors
(SMIHs). SMIHs include ﬁrst, second and third generation
agents. First generation SMIHs, such as quinine and verapamil
have been majorly preferred in several disorders because of
their pharmacological activity in addition to efﬂux pump
inhibitory property (Beck et al., 1988; Tsuruo et al., 1981).
Second and third generation SMIHs have been speciﬁcally
developed to inhibit efﬂux pump along with circumven-
tion of pharmacological interactions associated with ﬁrst
generation SMIHs (Woo et al., 2003; Asperen et al., 1997;
Bardelmeijer et al., 2000). However, SMIHs mediated risk of
accumulation, toxicity and anti-targeting cannot be completely
ignored. Hence, to overcome pharmacological interactions
associated with actives, several pharmacologically inactive
compounds have been successfully investigated for efﬂux
pump inhibitory activity. These inactives include polymeric
materials like Tween 80 and pluronic 85 (Friche et al., 1990;
Alakhov et al., 1996).
A number of polymers are known to interact with mem-
brane components that alter membrane transportability of
several drugs. This is more useful in cancer treatment, where
polymers inhibit membrane situated efﬂux pumps to improve
drug delivery inside the cell. Thorough understanding of inter-action between polymeric inhibitors and efﬂux pump is very
essential for developing better polymeric inhibitors with higher
safety, efﬁcacy and speciﬁcity. It has been reported that poly-
meric inhibitors may interact with or inhibit efﬂux pumps in
several ways such as [a] bypassing of drug efﬂux system by
drug-polymer conjugate (dendrimers); [b] inhibitor form con-
jugates with ATP that results into ATP depletion [poloxamer
unimers (Batrakova et al., 2001b), Myrj, Brij, dendrimers];
[c] inhibitors interfering with ATP-binding sites resulting in
site depletion for ATP binding [TPGS 1000 (Collnot et al.,
2007), dendrimers]; [d] blockage of trans-membrane situated
drug binding sites by polymeric inhibitor (thiomers) (Bernkop-
Schnurch and Grabovac, 2006); [e] interactions between
membrane and polymeric inhibitor that alters the integrity of
membrane lipids [polyethylene glycol (PEG), thiomers, pluron-
ics (Batrakova et al., 2001b), Myrj, Brij, dendrimers]. Jette
et al. (1998) have reported that SMIHs usually inhibit the
efﬂux pump by either modifying or completely blocking
efﬂux pump-drug binding sites. In previous studies, several
polymeric compounds with structural variations have been
established for their efﬂux pump inhibitory activity.
It has been observed that different membrane transporters
are continuously involved in transport of materials across
the biological membranes. Juliano and Ling (1976) have iden-
tiﬁed a membrane glycoprotein responsible for drug resistance
in colchicin drug resistant cells and speciﬁed it as ‘‘P-glycopro-
tein’’. Nature, localization and mechanisms of such transport-
ers have been previously discussed independently by Thiebaut
et al. (1987) and Cordon-Cardo et al. (1990). Additionally, the
role of such transporter proteins in drug development and
drug delivery have been discussed earlier by several researchers
(Girardin, 2006; Majumdar et al., 2004; Varma et al., 2006).
P-glycoprotein (PGP) is a transporter protein located in apical
membranes of epithelial cells which acts as an efﬂux pump. It
has been reported that these ATP dependent transporter pro-
teins are capable of active transport of several structurally di-
verse compounds outside cell, such as anticancer agents (Tsuji,
1998), immunosuppressants (Goldberg et al., 1988), steroid
hormones (Yang et al., 1989), calcium channel blockers (Yusa
and Tsuruo, 1989), beta-adrenoreceptor blockers and cardiac
glycosides (Karlsson et al., 1993; Lannoy and Silverman,
1992). Cancer cell shows resistance to multiple drugs (multi-
drug resistance cell) due to over expression of such transporter
proteins acting as efﬂux pumps. Additionally, these trans-
porter proteins are also present in healthy tissues, such as kid-
ney, placenta, liver, brain, testis and intestine (Thiebaut et al.,
1987; Cordon-Cardo et al., 1990). Leveque and Jehl (1995)
have reported that these transporter proteins take part in
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they inﬂuence pharmacokinetic processes. Choudhuri and
Klaassen (2006) have identiﬁed breast cancer resistant proteins
and multidrug resistant proteins (MRPs) 1 and 2 acting as
efﬂux pumps in the same way as PGP. Therefore, inhibition
of efﬂux pump is much essential step to enhance the transport
of anticancer agents (efﬂux pump substrates) into multidrug
resistance cells and improve drug delivery. This is a prerequi-
site in cancerous cells where presence of abundant number of
efﬂux pumps (PGPs) results in lowered concentrations of anti-
cancer drugs inside multidrug resistance cells and hence, thera-
peutic efﬁciency of such drugs get reduced or diminished totally.
Recently, pharmaceutical research is majorly concentrating
on formulating a drug into suitable dosage form that will
bypass the efﬂux pump transport system or developing novel
therapeutic molecules that will not act as efﬂux pump sub-
strates (Mazel et al., 2001; Raub, 2006). As well as on develop-
ment of efﬂux pump inhibiting agent to overcome multiple
drug resistance in cancerous cells (Varma et al., 2003). Several
researchers have demonstrated an increase in oral bioavailabil-
ity of efﬂux pump substrates when co-administered with efﬂux
pump inhibitors (Woo et al., 2003; Banerjee et al., 2000). Local
treatment of gastrointestinal carcinoma is an important exam-
ple involving combination of efﬂux pump inhibitors with can-
cer therapy and oral drug delivery. Apart from blood brain
barrier (BBB), efﬂux transporters are also responsible for
limited drug transport to brain (Pardridge, 1998). It has been
observed that co-administration of BBB located efﬂux pump
inhibitors with pump substrates results in enhanced transport
of later through BBB (Batrakova et al., 2001a).
Polymers are mainly classiﬁed into two main classes,
namely natural and synthetic polymers based on their origin.
Both natural and synthetic polymers have inﬂuenced the trans-
portability proﬁles of drug/s across biological membranes
through interaction with various membrane components. Such
polymer-membrane component interactions and their inﬂu-
ence on physiological performance of drug are discussed
brieﬂy with examples in following section.
Natural polymers
Several researchers have reported the use of natural polymers
as efﬂux pump inhibitors. Jodoin et al. (2002) and Honda et al.
(2004) have observed polyphenols of green tea and compounds
of grapefruit juice as natural polymeric efﬂux pump inhibitors.
Polysaccharides are the naturally occurring polymers with
ability to inhibit efﬂux pump. However, some polysaccharides
such as starch, cellulose, hyaluronic acid and chitosan are not
able to inhibit efﬂux pump. Carreno-Gomez and Duncan
(2002) have patented the use of polysaccharides, dendrimers
and surfactants as efﬂux pump inhibitors for the oral delivery
of antitumor, antineoplastic, antibiotic, antiviral, antifungal
and antidepressant drugs. It has been revealed with experimen-
tal data that anionic gums (polysaccharides), dextran and
sodium alginates possess ability to inhibit efﬂux pump. Natu-
ral gum polysaccharides include xanthan gum, gellan gum,
guar gum, agar, traganth etc. Carreno-Gomez and Duncan
(2002) have reported PGP efﬂux pump inhibitory activity of
xanthan gum that resulted in an enhanced accumulation of
PGP substrates vinblastin and doxorubicin inside gut cells.
However, enhanced serosal transport has been observed withvinblastin but not with doxorubicin (Carreno-Gomez and
Duncan, 2002). Gellan gum has shown efﬂux pump inhibitory
activity with increased serosal transport of vinblastin but with
unchanged tissue level. However, gellan gum has increased
both accumulation and serosal transport of doxorubicin. Dex-
tran has also shown concentration dependant effects on efﬂux
pump (Carreno-Gomez and Duncan, 2002). Carreno-Gomez
and Duncan (2002) have also investigated efﬂux pump inhibi-
tory activity of alginates such as ﬂavicam and ascophyllum. It
has been observed that ﬂavicam enhanced the cell accumula-
tion and serosal transport of doxorubicin in everted gut sac
cells. However, cell accumulation of vinblastin remains unaf-
fected (Carreno-Gomez and Duncan, 2002). Ascophyllum
has shown increase in cell accumulation of both vinblastin
and doxorubicin in everted gut sac cells. However, increase
in serosal transport of only vinblastin and not of doxorubicin
has been observed. Additionally, use of ascophyllum (250 mg/
kg) resulted in 1.7 folds increase in blood level (biodistribu-
tion) of radioactive labeled vinblastin with respect to control
after oral gavage in rats (Carreno-Gomez and Duncan, 2002).
Hori et al. (1978) have studied the effect of free fatty acids
as membrane components on the permeability of various drugs
across lipid bilayers derived from egg phosphatidylcholine
membranes and intestinal lipid membranes. In this study, free
fatty acids such as lauric, stearic, oleic, linoleic and linolenic
acid have been incorporated into the bilayer lipid membranes
derived from egg phosphatidylcholine. This study concludes
with enhancement in permeability coefﬁcients of several anio-
nic-charged acidic drugs such as p-aminobenzoic acid, salicylic
acid and p-aminosalicylic acid across phosphatidylcholine
membranes. Although the permeability of p-aminobenzoic
acid through intestinal lipid membranes was higher than that
of phosphatidylcholine membranes, a decrease in the perme-
ability coefﬁcient of p-aminobenzoic acid on addition of fatty
acids to intestinal lipid membranes has been observed (Hori
et al., 1978).
Synthetic polymers
Use of synthetic polymers as efﬂux pump inhibitors has been
revealed previously. Several copolymers of PEG such as
polyethylene oxide glycol, polyoxyethylene glycol have been
investigated for efﬂux pump inhibitory activity. Johnson
et al. (2002) have reported the efﬂux pump inhibitory activity
of PEG 400 (1–20%) with decrease in the basolateral to apical
transport of digoxin through stripped rat jejunal mucosa. Shen
et al. (2006) have investigated the efﬂux pump inhibitory activ-
ity of various concentrations (0.1–20% v/v or w/v) of PEG
400, 2000 and 20,000 and reported that the secretory transport
of rhodamine 123 (RHOD 123) get suppressed independent of
PEG molecular weights in isolated rat intestine. Additionally,
improved absorption of RHOD 123 has been reported from
solution formulations prepared using different concentrations
of PEG 20,000. Hugger et al. (2002) have reported an increase
in permeation of efﬂux pump substrates doxorubicin and pac-
litaxel through Caco-2 cell monolayers in presence of PEG
300. This was attributed to changes in the microenvironment
of Caco-2 cell membranes by modifying ﬂuidity of the polar
head group regions by PEG 300. It has been observed that
apical to basolateral transport of paclitaxel increases with an
increase in PEG 300 content and vice versa (Hugger et al.,
330 V.L. Gaikwad, M.S. Bhatia2002). Choi and Jo (2004) have observed an increase in
PEGylated paclitaxel uptake than unmodiﬁed paclitaxel fol-
lowing oral administration and concluded with improvement
in absorption of PEGylated water soluble prodrug due to
partial bypass of PGP efﬂux and CYP3A metabolism. Addi-
tionally, efﬂux pumps inhibitory activity of several polymeric
surfactants such as PEG based detergents have been revealed
previously by various researchers. Amongst them Tween 80
and D-Alpha-Tocopheryl Poly(ethylene glycol) Succinate
1000 (TPEGS 1000) were the most potential candidates.
Varma and Panchagnula (2005) have observed an improvement
in the oral bioavailability of PGP substrate paclitaxel (BCS
class IV) with use of TPEGS 1000 as the solubilizing agent.
This effect was attributed to improved paclitaxel solubility
and PGP inhibition by TPEGS 1000. Effect of TPEGS alkyl-
chain length on its efﬂux pump inhibitory activity have been
investigated by Collnot et al. (2006) and concluded TPEGS
1000 as the most potent efﬂux pump inhibitor amongst all
the tested ten different TPEGS derivatives. Amongst all poly-
sorbates, Tween 20, 40 and 80 have been reported as the most
potent efﬂux pump inhibitors. Friche et al. (1990) have inves-
tigated efﬂux pump inhibitory activity of Tween 80 and ob-
served an enhancement in accumulation of daunorubicin in
resistant Ehrlich ascites tumor cells. Shono et al. (2004) have
reported a decrease in efﬂux ratio of RHOD 123 in the
presence of Tween 80 when studied with excised rat intestinal
mucosa. Additionally, Zhang et al. (2003) have reported an
improvement in absorption of PGP substrate, digoxin in rats
with use of Tween 80.
Polyoxyethylene stearates (Myrj) and alkyl-Polyethylene
oxide surfactants (Brij) have also shown efﬂux pump inhibi-
tory activity. Lo (2003) have investigated the relationship
between the multidrug resistance modulating effect of pharma-
ceutical excipients and their hydrophilic–lipophilic balance
(HLB) values in Caco-2 cells and rat intestine. In this study,
efﬂux pump inhibitory activity of polyoxyethylene 40 stearate
has been proved by enhancement in intercellular accumulation
of epirubicin in Caco-2 cells (Lo, 2003). Additionally, Foger
et al. (2006) have demonstrated 2.4 folds increase in oral bio-
availability of PGP substrate RHOD 123 in rats from tablets
containing polyoxyethylene 40 stearate.
Poloxamers (pluronics) are amphiphilic copolymers consist-
ing of ethylene oxide (EO) and propylene oxide (PO) segments
arranged in alternative manner. Chain length of EO and PO is
found to affect the size and lipophilicity of pluronics. Pluronics
mediated efﬂux pump inhibition was found to be more prom-
ising in BBB drug delivery and cancer therapy. Batrakova et al.
(2001b) have reported that efﬂux pump inhibitory activity of
pluronics was mediated by ATPase inhibition followed by
ATP depletion and its effect on membrane ﬂuidization. Miller
et al. (1997) have revealed the concentration dependent efﬂux
pump inhibitory effect of pluronic 85 in brain microvessel
endothelial cell monolayers using RHOD 123 as model drug.
Furthermore, it has been demonstrated that the efﬂux pump
inhibitory effect of pluronics get reduced when its concentra-
tion reaches toward critical micelle concentration (CMC).
Banerjee et al. (2000) and Jagannath et al. (1999), in separate
studies have demonstrated the PGP efﬂux pump inhibitory
activity of CRL-1605 copolymer to improve tobramycin and
amikacin oral uptake. Kabanov et al. (2003) have discussed
the different mechanisms behind efﬂux pump inhibitory activ-
ity of pluronics and its role in delivery of efﬂux pump sub-strates across BBB. Batrakova et al. (1999a) have performed
in vitro permeation studies using polarized bovine brain micro-
vessel endothelial cells and demonstrated that pluronic P85 in-
creases permeability of several efﬂux pump substrates such as
doxorubicin, paclitaxel and etoposide across BBB. Addition-
ally, Batrakova et al. (2001a) have reported that pluronic
P85 was responsible for prolongation of residence time and
improved concentration of digoxin in the brain of wild type
mice. In cancer therapy, polymers have been used commonly
to overcome multidrug resistance either by inhibition of efﬂux
transporter proteins or by evading efﬂux pump transport sys-
tem. Kabanov et al. (2002) have thoroughly reviewed the
importance of pluronics in cancer therapy. Alakhov et al.
(1999) have observed that several types of cancers can be efﬁ-
ciently treated in vivo by using doxorubicin and pluronic for-
mulation. In separate studies, Venne et al. (1996) and
Batrakova et al. (1999b) have revealed PGP inhibition as the
mechanism behind inhibitory activity of pluronics, where an
increase in doxorubicin content has been observed in PGP
expressing cells but not in non-PGP expressing cell lines. Addi-
tionally, several researchers have demonstrated no increase in
non-PGP substrates accumulation inside resistant cells with
use of pluronics (Batrakova et al., 1998, 2001a; Miller et al.,
1997). Furthermore, it has been reported that pluronics can
also inhibit MRP 1 and 2 types of efﬂux pumps.
Targeted design of efﬂux pump inhibitors is quite difﬁcult
due to the presence of numerous binding sites on efﬂux pump,
such as PGP contains four different drug binding sites (Dey
et al., 1977; Pascaud et al., 1998; Shapiro et al., 1999; Lugo
and Sharom, 2005). Additionally, development of polymeric
inhibitors of interest for speciﬁc efﬂux pump is yet again more
complex due to the involvement of other factors such as unspe-
ciﬁc interactions with the cell membrane in efﬂux pump inhibi-
tion. Various mechanisms involved in interaction between
polymeric inhibitors and efﬂux pumps have been summarized
in Table 1.
Pavlov et al. (2009) have studied the interaction of copoly-
mers of EO and dimethylsiloxane with model biological mem-
branes and cancerous cells, where an enhancement in
permeability of model membranes in the presence of copoly-
mers has been observed. It has been observed that Pluronic
L61 at its low nontoxic concentrations showed a decrease in
the concentration of doxorubicin by a factor of 30, which is
toxic to cancerous cells.
The most important function of cell membrane is to control
the material transport into and out of the cell. Interruption in
this function due to loss of membrane integrity leads to gener-
ation of transient pores in the membrane structure causing cell
necrosis. Therefore sealing of porated membrane is an impor-
tant phenomenon, which can be accomplished in a natural way
or with use of several surfactants.
Maskarinec et al. (2005) have studied the membrane sealing
property of several polymers such as poloxamers, poloxamine,
etc. Industrial use of poloxamer copolymers as emulsifying,
wetting, thickening, coating, solubilizing, stabilizing, dispers-
ing, lubricating, and foaming agent has been already proved
(Chu and Zhou, 1996). Additionally, poloxamers can also be
used to restore the membrane integrity attributed to its ability
of interacting with the lipid bilayers and sealing the structur-
ally damaged membranes.
Several researchers have indicated the use of poloxamer 188
as membrane sealing agent due to its medical safety record
Table 1 Mechanisms behind interaction between polymeric inhibitors and efﬂux pump.
Sr.
No.
Mechanism of interaction Polymeric inhibitor
1. Bypass of drug eﬄux system by drug-polymer conjugate Dendrimers*
2. Inhibitors form conjugates with ATP that result in ATP depletion Poloxamer unimers[42], Myrj, Brij, Dendrimers*
3. Inhibitors interfering with ATP-binding sites resulting into site depletion
for ATP binding
TPGS 1000[69], Dendrimers*
4. Blockage of trans-membrane situated drug binding sites by polymeric
inhibitor
Thiomers[68]
5. Interactions between membrane and polymeric inhibitor that alters the
integrity of membrane lipids
PEG, Thiomers, Pluronics[42], Myrj, Brij, Dendrimers*
* Possibly by mentioned mechanism as exact mechanism is not clear.
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Frim et al., 2004; Marks et al., 1998, 2001; Hannig and Lee,
2000a). Additionally, poloxamine 1107 has also shown mem-
brane sealing capability (Palmer et al., 1998; Hannig et al.,
2000b; Greenebaum et al., 2004; Terry et al., 1999). These
polymers selectively get inserted in the damaged portions of
the membrane where low lipid packing density with respect
to intact cell membrane density has been observed. However,
as soon as the membrane lipid packing density is improved
or membrane integrity is restored, the inserted polymer is
‘‘squeezed out’’ of the lipid ﬁlm signifying the cell free of the
inserted polymer. Maskarinec and Lee (2003) and Weingarten
et al. (1991) in separate studies have reported the high surface
pressure as a possible mechanism for poloxamer 188 squeezing
out of lipid monolayers. It has been concluded that poloxamer
aids to improve the local lipid packing density in the damaged
bilayers of the membrane and can be used as a membrane seal-
ant for therapeutic purposes.
D’Emanuele et al. (2004) have demonstrated an improve-
ment in apical to basolateral transport of propranolol (PGP
substrate) with use of generation 3 polyamidoamine dendri-
mers through Caco-2 monolayers attributed to bypass PGP
transport system instead of inhibition. This was supported
by no more improvement in propranolol transport in the pres-
ence of recognized PGP inhibitor such as cyclosporine A. Fur-
thermore, it has been observed that conjugation of dendrimer
with efﬂux pump substrates is not essential but presence of
former may lead to enhancement in substrate transport. This
was supported by increased vinblastine and doxorubicin accu-
mulation in presence of generation 3 dendrimer with use of gut
sacs (Carreno-Gomez and Duncan, 2002).
Werle and Hoffer (2006) have demonstrated the ability of
thiomers (thiolated polymers) to inhibit efﬂux pump. Several
other researchers have revealed the dependence of inhibitory
activity of thiomers on presence of thiol groups (Bromberg,
2001; Bromberg and Alakhov, 2003; Luessen et al., 1994,
1997). Foger et al. (2007) have revealed an improved uptake
of the saquinavir (efﬂux pump substrate) in presence of thio-
mer-glutathione system. These studies indicate that thiomer
is a potential candidate to improve transport of substrates of
different efﬂux pumps such as MRP and PGP. Iqbal et al.
(2010) have improved the PGP inhibitory properties of PEG
by covalent attachment of thiol moieties. PEG was grafted
with polyethylenimine and subsequently thiolated with c-thio-
butyrolatone. This novel thiolated PEG-g-polyethylenimine co
polymer has been further evaluated for the transport of
RHOD 123 as PGP substrate across freshly excised rat intesti-
nal mucosa. Thiolated co polymer (at 0.5% w/v) has shownprofound effect on absorptive transport of RHOD 123 com-
pared to other tested compounds, where it has increased
RHOD 123 transport up to 3.3-folds than control (RHOD
123 without inhibitor). In addition to PGP inhibition, Foger
et al. (2007) have observed that thiolated polymers can also in-
hibit intestinal efﬂux pumps (MRP) that have resulted in mod-
ulation of drug absorption. It has been observed that thiomers
are promising candidates for inhibition of efﬂux transporters
such as PGP and MRP that affect the delivery of various drugs
to target site. Greindl et al. (2009) have evaluated the thiolated
poly(acrylic acid) as MRP2 inhibitor to modulate MRP2 efﬂux
pump substrate absorption using freshly excised rat intestinal
mucosa mounted in Ussing-type chambers. An increase up
to 3.8-fold in area under curve in the plasma concentration
time plot of sulforhodamine 101 (MRP2 substrate) in presence
of poly(acrylic acid)-cysteine solution compared to buffer con-
trol has been reported.
Chen and Schluesener (2010) have studied the effect of mul-
ti-walled carbon nanotubes on transportability of several com-
pounds, such as ﬂuorescein diacetate, carboxyﬂuorescein
diacetate, RHOD 123 and doxorubicin across rat astrocytes
cell membrane. These compounds are either prosubstrates or
substrates of multidrug transporter proteins. It has been
observed that cellular uptake of doxorubicin get inhibited sig-
niﬁcantly in presence of multi-walled carbon nanotubes attrib-
uted to mode of loading of doxorubicin. However, cellular
uptake of other drugs remains unaffected. After an efﬂux per-
iod, a notable high retention of ﬂuorescein diacetate, carboxy-
ﬂuorescein diacetate and RHOD 123 within cells exposed to
multi-walled carbon nanotubes have been reported. Quinton
and Philpott, (1973) have studied the effect of several cationic
polymers such as poly-L-lysine, protamine and histone on rab-
bit gall bladder epithelial cells to explore possible functions
carried out by anionic sites in the membrane. All tested
cationic polymers have shown similar changes in membrane
structure as examined by bathing the tissue in number of Ring-
er’s solutions containing cationic polymers at different concen-
trations. These changes include loss of rigidity by microvilli, an
apparent increase in membranes permeability, etc. It has been
observed that ﬁxed anionic sites in the membrane played major
roles in stabilizing epithelial membrane structure as well as
maintaining both the anatomical form and physiological integ-
rity of the cell (Quinton and Philpott, 1973).
ATP-binding cassette (ABC) transport proteins reported to
mediate the transport of several structurally diverse
compounds through cell membranes. These compounds in-
clude amino acids, ions, peptides and variety of drugs (Hig-
gins, 1992). ABCB1 transporters (ABC transporter
332 V.L. Gaikwad, M.S. Bhatiasubfamily) such as PGP are responsible for efﬂux of chemically
modiﬁed and conjugated compounds by cytochrome P450 en-
zymes (Szakacs et al., 2006). Hanke et al. (2010) have studied
the interactions of commonly used nonionic surfactants with
the human efﬂux transporters ABCB1 (PGP) and ABCC2
(MRP2). These efﬂux transporters are majorly responsible
for limited oral bioavailability of several drugs (Szakacs
et al., 2006; Fricker and Miller, 2002). In this study, the inter-
actions of structurally diverse nonionic surfactants such as,
cremophor EL, cremophor RH 40, polysorbate 80, pluronic
PE 10300, vitamin E TPGS 1000 and sucrose ester L-1695 with
above mentioned efﬂux transporters have been studied. In
addition to solubilizing property, several researchers have re-
ported the use of nonionic surfactants as inhibitors of human
efﬂux transporter ABCB1 that inﬂuences the disposition of
many drugs (Batrakova et al., 2003; Tayrouz et al., 2003;
Tellingen et al., 1999; Mountﬁeld et al., 2000; Rege et al.,
2002). Additionally, because of earlier identiﬁcation of ABCB1
than ABCC2, the interactions between nonionic surfactants
and the efﬂux transporter ABCB1 have been studied broadly
compared to ABCC2, where limited study on interactions with
surfactants have been performed (Juliano and Ling, 1976;
Collnot et al., 2006; Batrakova et al., 2003; Dudeja et al.,
1995; Woodcock et al., 1990; Paulusma et al., 1996). Interac-
tions of pharmaceutical surfactants such as cremophor EL or
polysorbate 80 with ABCB1 have been studied completely,
but not with ABCC2. An inhibitory activity of cremophor
EL, vitamin E TPGS 1000 and polysorbate 80 (at higher con-
centration) on both efﬂux transporters have been reported. It
has been observed that Pluronic PE 10300 and sucrose ester
L-1695 inhibit ABCB1 but not ABCC2. However, Cremophor
RH 40 is able to inhibit ABCC2 but not ABCB1 (Hanke et al.,
2010).
Conclusion
In addition to physicochemical aspects of polymers, their inter-
action with biological membranes and its components must
also be strictly considered while selecting polymer for desired
formulation. Polymers have shown both beneﬁcial and harmful
effects on drugs bioavailability, especially in case of drugs used
in cancer treatment. Therefore, biological interaction of poly-
mer/s inﬂuencing transportability proﬁle of actives must be
greatly considered to achieve maximum drug bioavailability.
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